 CAMBRIDGE, Mass., Sept. 22, 2021 PRNewswire -- Synlogic Nasdaq: SYBX a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of 3.00 per share. 